[CLSTR]
API
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 2 sources · 17 days · First seen · Last updated

L&K Bio US spinal implant market expansion

Overview

L&K Bio, through its US subsidiary L&K Spine, has initiated a business execution schedule for its spinal implant products following participation in the North American Spine Society meeting in Texas. The company has been promoting its BluEX-C cervical expandable cage, which received FDA approval in May, and reported reaching 50 cumulative cervical surgery levels in the US market.

To further its presence, L&K Biomed signed a distribution agreement with New Jersey based Precision Spine, Inc. for the BluEX-C device. This follows a previous contract with Medtronic for lumbar expandable cages. The company is also pursuing a ‘New Cervical Project’ in technical collaboration with spinal expert Dr. K. Daniel Riew to develop products for corpectomy, while collecting procedure data to develop future AI-integrated smart systems.

Entities

CDER Exclusivity Board · US Food and Drug Administration · NASS · L&K Biomed · K. Daniel Riew

Timeline

  1. [BUSINESS] 2 sources
    L&K Biomed secures US distribution deal for BluEX-C cervical implants

    L&K Biomed's US subsidiary signed a deal with Precision Spine to distribute BluEX-C cervical implants, expanding its footprint in the US spinal medical device market.

  2. [BUSINESS] 3 sources
    L&K Bio accelerates US spinal implant business via NASS 2026

    L&K Bio's US subsidiary, L&K Spine, has finalized business schedules for its FDA-approved BluEX-C cervical implants following participation in the NASS 2026 conference in Texas.

Sources

biotimes.co.kr · socialvalue.kr